Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index; 31 of the 46 sources its claims cite were checked for support.
Abstract
Metal-dependent histone deacetylases (HDACs) are key epigenetic regulators that represent promising therapeutic targets for the treatment of numerous human diseases. Yet the currently FDA-approved HDAC inhibitors nonspecifically target at least several of the 11 structurally similar but functionally different HDAC isozymes, which hampers their broad usage in clinical settings. Selective inhibitors targeting single HDAC isozymes are being developed, but precise understanding in molecular terms of their selectivity remains sparse. Here, we show that HDAC8-selective inhibitors adopt a L-shaped conformation required for their binding to a HDAC8-specific pocket formed by HDAC8 catalytic tyrosine and HDAC8 L1 and L6 loops. In other HDAC isozymes, a L1-L6 lock sterically prevents L-shaped inhibitor binding. Shielding of the HDAC8-specific pocket by protein engineering decreases potency of HDAC8-selective inhibitors and affects catalytic activity. Collectively, our results unravel key HDAC8 active site structural and functional determinants important for the design of next-generation chemical probes and epigenetic drugs.
Overview
CoChat Summary
## TL;DR
This paper shows that HDAC8-selective inhibitors bind a specific HDAC8 pocket shaped by the catalytic tyrosine and the L1/L6 loops, and that an L-shaped inhibitor conformation is required for this selectivity. The authors combine crystal structures, mutagenesis, biophysical assays, docking, MD, and schistosome assays to show that small changes in inhibitor structure or loop conformation strongly affect potency and selectivity.
## Key findings
- PCI-34051, NCC-149, and Quisinostat (QSN) inhibited hHDAC8 and smHDAC8 in the submicromolar range; the reported IC50 values were 77.7 ± 18.1 nM, 44 ± 4.9 nM, and 64.4 ± 3.4 nM for hHDAC8, and 435.8 ± 61 nM, 95.4 ± 9.3 nM, and 303.4 ± 39 nM for smHDAC8, respectively.
- The crystal structures showed that the HDAC8-selective inhibitors PCI-34051 and NCC-149 adopt an L-shaped conformation and contact the catalytic tyrosine and L6 loop, whereas QSN binds in a more canonical mode.
- HDAC8-selective inhibition was attributed to a specific “HDAC8-selective pocket” formed by the catalytic tyrosine plus L1 and L6 loop residues; in other HDAC isozymes, a L1-L6 lock sterically blocks this pocket.
- Mutating the L1/L6 region reduced activity and weakened inhibition: all mutants had about a 5°C lower Tm than wild type, hHDAC8 mutants showed around 10-fold activity loss in point mutants/L6 replacements, and the triple mutant showed almost no activity; PCI-34051 IC50 increased by more than 64-fold for the triple mutant.
## Methods
- Combined structural, biochemical, and functional analysis of hHDAC8 and smHDAC8, including X-ray crystallography of inhibitor-bound HDAC8 complexes, mutational analysis of L1/L6 loop variants, activity/inhibition assays, ITC, DSF, docking, MD simulations, and parasite culture assays.
- Used recombinant WT and mutant hHDAC8 and smHDAC8 proteins expressed in bacteria; apo smHDAC8 crystals were soaked with inhibitors, and one hHDAC8-mL6/QSN complex structure was obtained by co-crystallization.
- Tested inhibitor effects on S. mansoni schistosomula and adult worms using microscopy-based viability and egg-production assays; schistosomula were treated at 25, 50, and 100 µM, and TUNEL was used to detect DNA strand breaks after 100 µM treatment.
## Limitations
- The authors state that they were not able to obtain well-diffracting crystals of hHDAC8 complexed with PCI-34051, NCC-149, and QSN; only the hHDAC8-mL6/QSN complex yielded exploitable structural data.
- They note that several structures, including QSN bound to hHDAC8-mL6, are influenced by crystal packing, making it difficult to know whether the observed conformations are biologically favored in solution.
- Evident from the text: the mutational analysis was limited by solubility, because all smHDAC8 mutants except point mutants were insoluble, which restricted structural/biophysical follow-up.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 6 Not checked · 157 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“we previously observed a very similar binding mode to smHDAC8 for another pan-HDAC inhibitor, M344, including an interaction between D100 and the M344 internal amide group 30”
What the sources say
- Supportedcites [30] 30. Marek, M.; Kannan, S.; Hauser, A. T.; Moraes Mourao, M.; Caby, S.; Cura, V.; Stolfa, D. A.; Schmidtkunz, K.; Lancelot, J.; Andrade, L.; Renaud, J. P.; Oliveira, G.; Sippl, W.; Jung, M.; Cavarelli, J.; Pierce, R. J.; Romier, C. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog 2013, 9, e1003645. source
The “Ligand-induced gating of the catalytic pocket” section describes the smHDAC8–M344 complex and says M344 binding is stabilized by an interaction between its N10 atom and the smHDAC8 D100 carboxylate. The paper also identifies M344 as a generic HDAC inhibitor. Page numbers are not available in the supplied copy. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a similar binding mode was also observed upon SAHA binding to human HDAC2 in a crystal lattice-free environment 39”
What the sources say
- Partly supportedcites [39] 39. Lauffer, B. E.; Mintzer, R.; Fong, R.; Mukund, S.; Tam, C.; Zilberleyb, I.; Flicke, B.; Ritscher, A.; Fedorowicz, G.; Vallero, R.; Ortwine, D. F.; Gunzner, J.; Modrusan, Z.; Neumann, L.; Koth, C. M.; Lupardus, P. J.; Kaminker, J. S.; Heise, C. E.; Steiner, P. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem 2013, 288, 26926-26943. sourceExperimental — accuracy not yet measured
The structural-analysis section reports SAHA bound to HDAC2 and describes its binding mode. The crystallization and data-collection section says the structure was determined from crystals soaked with SAHA, so this paper does not support the claim that the observation was made in a crystal lattice-free environment. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In HDAC8, the L1 and L2 loops have been shown to display flexibility, being able to change their conformation to adapt to different inhibitors such as the large Largazole inhibitor and its analogues (Figure S7) 40, 41”
What the sources say
- Partly supportedcites [40] 40. Cole, K. E.; Dowling, D. P.; Boone, M. A.; Phillips, A. J.; Christianson, D. W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J Am Chem Soc 2011, 133, 12474-12477. sourceExperimental — accuracy not yet measured
The discussion of Fig. 3b describes L1 and L2 loop shifts that accommodate bulky largazole thiol and compares some shifts with those seen for another inhibitor, M344. It discusses largazole analogues, but only suggests that one analogue likely triggers a similar change; it does not show L1 and L2 adapting to largazole analogues. (LLM, conf=0.86)
- Supportedcites [41] 41. Decroos, C.; Clausen, D. J.; Haines, B. E.; Wiest, O.; Williams, R. M.; Christianson, D. W. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8. Biochemistry 2015, 54, 2126-2135. source
The Discussion states that binding three Largazole analogues triggers changes in HDAC8’s L2 loop that propagate to the L1 loop, and that these changes differ from those in the HDAC8–Largazole complex. The Concluding Remarks likewise describe flexible L1 and L2 loops accommodating Largazole and its analogues. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previous work on the selective inhibition of smHDAC8 has yielded the development of an inhibitor series of 3-benzamido-benzohydroxamates that show strong selectivity for smHDAC8 and hHDAC8 over other human HDACs 29”
What the sources say
- Supportedcites [29] 29. Heimburg, T.; Chakrabarti, A.; Lancelot, J.; Marek, M.; Melesina, J.; Hauser, A. T.; Shaik, T. B.; Duclaud, S.; Robaa, D.; Erdmann, F.; Schmidt, M.; Romier, C.; Pierce, R. J.; Jung, M.; Sippl, W. Structure-based design and synthesis of novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of schistosomiasis. J Med Chem 2016, 59, 2423-2435. source
The STRUCTURAL VALIDATION section states that the 3-amido(benzamido)-benzohydroxamates (7a-c, extended to 7d-7z in SYNTHESIS) were active in the nanomolar range and that 'all compounds show specificity for the HDAC8 isoforms over the other human HDACs tested (HDAC1 and 6)', i.e. both smHDAC8 and hHDAC8. CONCLUSIONS repeats that 'the presented compounds demonstrated high selectivity for smHDAC8 over the major human HDAC isoforms HDAC1 and HDAC6, and some compounds even showed a preference for smHDAC8 over its human ortholog hHDAC8', and Table 1 gives the supporting IC50 values. The only qualifier the paraphrase softens is 'tested': the paper's comparison panel is HDAC1 and HDAC6 rather than all human HDACs, which is the paper's own framing. (LLM, conf=0.85)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have previously shown that our smHDAC8 crystals can be used to look at inhibitor binding in a crystal latticeunbiased manner 29, 30, 55-58 .”
What the sources say
- Partly supportedcites [29] 29. Heimburg, T.; Chakrabarti, A.; Lancelot, J.; Marek, M.; Melesina, J.; Hauser, A. T.; Shaik, T. B.; Duclaud, S.; Robaa, D.; Erdmann, F.; Schmidt, M.; Romier, C.; Pierce, R. J.; Jung, M.; Sippl, W. Structure-based design and synthesis of novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of schistosomiasis. J Med Chem 2016, 59, 2423-2435. sourceExperimental — accuracy not yet measured
Our copy of Heimburg et al. (2016) does demonstrate that smHDAC8 crystals can be used to look at inhibitor binding: native crystals were soaked in mother liquor supplemented with inhibitor 7a (Crystallization and X-ray data collection), and the resulting 2.3 Å smHDAC8/7a complex structure is used to describe the binding mode in the active-site pocket (STRUCTURAL VALIDATION; PDB 5FUE, Structure determination/model building and refinement). However, no passage in our copy characterises these crystals as permitting binding to be observed 'in a crystal lattice-unbiased manner' — the paper only notes that the complex crystals share the native crystals' space group (P1) and unit cell, and nowhere comments on lattice effects or their absence. That methodological qualifier is therefore attributed to this source without support from it. (LLM, conf=0.70)
- Partly supportedcites [30] 30. Marek, M.; Kannan, S.; Hauser, A. T.; Moraes Mourao, M.; Caby, S.; Cura, V.; Stolfa, D. A.; Schmidtkunz, K.; Lancelot, J.; Andrade, L.; Renaud, J. P.; Oliveira, G.; Sippl, W.; Jung, M.; Cavarelli, J.; Pierce, R. J.; Romier, C. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog 2013, 9, e1003645. sourceExperimental — accuracy not yet measured
The ‘Structure-guided design of specific inhibitors’ section (page unavailable) reports that soaking smHDAC8 crystals yielded structures showing how J1038 and J1075 bind. The paper does not establish that the observed binding is unbiased by the crystal lattice, so that qualification is unsupported. (LLM, conf=0.84)
- Partly supportedcites [55] 55. Bayer, T.; Chakrabarti, A.; Lancelot, J.; Shaik, T. B.; Hausmann, K.; Melesina, J.; Schmidtkunz, K.; Marek, M.; Erdmann, F.; Schmidt, M.; Robaa, D.; Romier, C.; Pierce, R. J.; Jung, M.; Sippl, W. Synthesis, crystallization studies, and in vitro characterization of cinnamic acid derivatives as smhdac8 inhibitors for the treatment of schistosomiasis. ChemMedChem 2018, 13, 1517-1529. sourceExperimental — accuracy not yet measured
Our copy does show these SmHDAC8 crystals being used to examine inhibitor binding: four SmHDAC8/inhibitor complexes were soaked, solved and refined (Crystallization and X-ray data collection; Structure determination, model building and refinement), and the complexes 'belonged to the same space group (P1) and had the same unit cell as native SmHDAC8 crystals'. The Structure-activity relationship and structural validation section reports binding 'in different orientations in the active site pocket' with both flipped-in and flipped-out Phe151 in the 9b structure, and the Docking study confirms binding 'reminiscent of our previous crystallographic analyses'. However, no passage in our copy (searched: 'lattice-unbiased', 'crystal packing', 'low symmetry P1 not constraining binding', 'soaking/native comparison') states or argues that this lattice permits assessment of inhibitor binding free of crystal-lattice bias — that methodological qualifier is the part attributed to this source that it does not support. (LLM, conf=0.68)
- Not checked — no full text of the sourcecites [56] 56. Heimburg, T.; Kolbinger, F. R.; Zeyen, P.; Ghazy, E.; Herp, D.; Schmidtkunz, K.; Melesina, J.; Shaik, T. B.; Erdmann, F.; Schmidt, M.; Romier, C.; Robaa, D.; Witt, O.; Oehme, I.; Jung, M.; Sippl, W. Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity. J Med Chem 2017, 60, 10188-10204. source
- Partly supportedcites [57] 57. Simoben, C. V.; Robaa, D.; Chakrabarti, A.; Schmidtkunz, K.; Marek, M.; Lancelot, J.; Kannan, S.; Melesina, J.; Shaik, T. B.; Pierce, R. J.; Romier, C.; Jung, M.; Sippl, W. A novel class of Schistosoma mansoni histone deacetylase 8 (HDAC8) inhibitors identified by structure-based virtual screening and in vitro testing. Molecules 2018, 23, e566. sourceExperimental — accuracy not yet measured
Section 2.2 (page unavailable) reports an smHDAC8–J1036 crystal structure and describes the inhibitor’s binding in the active-site pocket. Section 3.4 (page unavailable) describes soaking smHDAC8 crystals with J1036. Neither section establishes that the observed binding is unbiased by crystal-lattice contacts. (LLM, conf=0.84)
- Partly supportedcites [58] 58. Stolfa, D. A.; Marek, M.; Lancelot, J.; Hauser, A. T.; Walter, A.; Leproult, E.; Melesina, J.; Rumpf, T.; Wurtz, J. M.; Cavarelli, J.; Sippl, W.; Pierce, R. J.; Romier, C.; Jung, M. Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen Schistosoma mansoni. J Mol Biol 2014, 426, 3442-3453. sourceExperimental — accuracy not yet measured
Our copy of Stolfa et al. (2014) does use smHDAC8 crystals to examine inhibitor binding: the section 'Crystal structure of smHDAC8 in complex with the mercaptoacetamide inhibitor 1a' reports a 2.3 A co-crystal in which 1a 'binds to each monomer in the asymmetric unit of the crystal with full occupancy' with well-defined, unambiguously interpretable density in the catalytic pocket (zinc ion and Y341), and 'Structure determination, model building and refinement' notes the complex crystallizes in the same space group (P1) and unit cell as native smHDAC8. However, no passage in our copy addresses the 'crystal lattice-unbiased' qualifier: searches for crystal lattice, packing or lattice-contact effects returned nothing that comments on whether the lattice constrains or biases the observed binding mode (the only per-monomer detail given is variable C-C-S-Zn dihedral angles: 28.4, 26.8, -17.0 and 13.5). So the source supports the general point that smHDAC8 co-crystals reveal inhibitor binding, but not the specific methodological claim of lattice-independent/unbiased observation asserted in the citing sentence. (LLM, conf=0.66)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
95 more claims
Create a free account to see all 177 claims and to verify the 4 references still open.
- It may state two separate claims as one. 62
- Probably not a substantial claim. 17
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977) · Journal of Computational Physics · doi:10.1016/0021-9991(77)90098-5 · Cited by 21,239
Development and testing of a general amber force field
Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20035 · Cited by 19,506
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
The missing term in effective pair potentials
Berendsen, H. J. C., Grigera, J. R., & Straatsma, T. P. (1987) · The Journal of Physical Chemistry · doi:10.1021/j100308a038 · Cited by 13,345
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
Cited by
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Zhao, C., Dong, H., Xu, Q., & Zhang, Y. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1725470 · Cited by 147
“amino acid residues at the solvent-exposed region of the enzyme [5,22,23].”
BackgroundNext-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 157
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Self-citationHistone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Banerjee, S., Adhikari, N., Amin, S. A., & Jha, T. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.039 · Cited by 108
HDAC-targeting epigenetic modulators for cancer immunotherapy
Cheng, B., Pan, W., Xiao, Y., Ding, Z., Zhou, Y., Fei, X., Liu, J., Su, Z., Peng, X., & Chen, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116129 · Cited by 122
Rodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 70
Wang, Y., Abrol, R., Mak, J. Y. W., Gupta, K. D., Ramnath, D., Karunakaran, D., Fairlie, D. P., & Sweet, M. J. (2022) · FEBS Journal · doi:10.1111/febs.16437 · Cited by 81
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
“revealed that the binding mode of PCI-34051 and NCC-149 with Schistosoma mansoni HDAC8 (smHDAC8) through X-ray crystallization [120].”
BackgroundUpadhyay, N., Tilekar, K. N., Jänsch, N., Schweipert, M., Hess, J. D., Macias, L. G.-F., Mrówka, P., Aguilera, R. J., Choe, J., Meyer‐Almes, F., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103934 · Cited by 56
“The selectivity of hydroxamate inhibitors was recently attributed to their L-shape and binding to a subpocket between L1- and L6-loop at the outer rim of the active site pocket that is unique for HDAC8 [14].”
BackgroundTargeting HDAC Complexes in Asthma and COPD
Zwinderman, M. R. H., de Weerd, S., & Dekker, F. J. (2019) · Epigenomes · doi:10.3390/epigenomes3030019 · Cited by 52
“The selectivity difference between these hydroxamic acid HDACi is poorly understood but is under active investigation [99].”
BackgroundCampiani, G., Cavella, C., Osko, J. D., Brindisi, M., Relitti, N., Brogi, S., Saraswati, A. P., Federico, S., Chemi, G., Maramai, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00184 · Cited by 66
Self-citationSelective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)
Chotitumnavee, J., Yamashita, Y., Takahashi, Y., Takada, Y., Iida, T., Oba, M., Itoh, Y., & Suzuki, T. (2022) · Chemical Communications · doi:10.1039/d2cc00272h · Cited by 59
Self-citationIbrahim, H. S., Abdelsalam, M., Zeyn, Y., Zessin, M., Mustafa, A.-H. M., Fischer, M. A., Zeyen, P., Sun, P., Bülbül, E. F., Vecchio, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010369 · Cited by 50
Self-citationTilekar, K. N., Upadhyay, N., Jänsch, N., Schweipert, M., Mrówka, P., Meyer‐Almes, F., & Ramaa, C. S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103522 · Cited by 52
Huang, J., Zhang, J., Xu, W., Wu, Q., Zeng, R., Liu, Z., Tao, W., Chen, Q., Wang, Y., & Zhu, W. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00739 · Cited by 53
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Fontana, A., Cursaro, I., Carullo, G., Gemma, S., Butini, S., & Campiani, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710014 · Cited by 50
“These findings emphasized that selective HDAC8 inhibition could be achieved by properly analysing the potential conformations that compounds can adopt in the catalytic site, given that small structural modifications might affect the binding interactions, and consequently, the affinity and the selectivity towards a spe…”
BackgroundInfluentialHassan, M. M., Israelian, J., Nawar, N., Ganda, G., Manaswiyoungkul, P., Raouf, Y. S., Armstrong, D., Sedighi, A., Olaoye, O. O., Erdogan, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01025 · Cited by 41
A distal regulatory region of a class I human histone deacetylase
Werbeck, N. D., Shukla, V. K., Kunze, M. B. A., Yalinca, H., Pritchard, R. B., Siemons, L., Mondal, S., Greenwood, S. O. R., Kirkpatrick, J., Marson, C. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17610-w · Cited by 40
Sinatra, L., Vogelmann, A., Friedrich, F., Tararina, M. A., Neuwirt, E., Colcerasa, A., König, P., Toy, L., Yesiloglu, T. Z., Hilscher, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01385 · Cited by 47
Self-citationDarwish, S., Ghazy, E., Heimburg, T., Herp, D., Zeyen, P., Salem-Altintas, R., Ridinger, J., Schmidtkunz, K., Robaa, D., Erdmann, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147535 · Cited by 48
“Crystallographic studies, as well as molecular docking studies on several HDAC subtypes [51], revealed that the selectivity of this series of compounds can be attributed to the fact that the aromatic capping group occupies an HDAC8-specific pocket, which is absent in the other HDAC isoforms.”
BackgroundSelf-citationTilekar, K. N., Upadhyay, N., Schweipert, M., Hess, J. D., Macias, L. G.-F., Mrówka, P., Meyer‐Almes, F., Aguilera, R. J., Iancu, C. V., Choe, J., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105512 · Cited by 40
Ghazy, E., Zeyen, P., Herp, D., Hügle, M., Schmidtkunz, K., Erdmann, F., Robaa, D., Schmidt, M., Morales, E., Romier, C., et al. (2020) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2020.112338 · Cited by 27
“Recent research also revealed some unique structural features in this isoform, which distinguish it from other HDACs and which can be utilized to design selective inhibitors [60].”
BackgroundSelf-citationDiscovery of highly potent HDAC8 PROTACs with anti-tumor activity
Zhao, C., Chen, D., Suo, F., Setroikromo, R., Quax, W. J., & Dekker, F. J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106546 · Cited by 41
Peng, J., Xie, F., Qin, P., Liu, Y., Niu, H., Sun, J., Xue, H., Zhao, Q., Liu, J., & Wu, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106622 · Cited by 38
Baselious, F., Hilscher, S., Robaa, D., Barinka, C., Schutkowski, M., & Sippl, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021358 · Cited by 32
Self-citationSignificance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors
Frühauf, A., Behringer, M., & Meyer‐Almes, F. (2023) · Molecules · doi:10.3390/molecules28155686 · Cited by 42
“[79] as probe to explore isozyme selectivity.”
Amin, S. A., Khatun, S., Gayen, S., Das, S., & Jha, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115594 · Cited by 34
The important role of histone deacetylases in modulating vascular physiology and arteriosclerosis
Zhao, T. C., Wang, Z., & Zhao, Y. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.020 · Cited by 30
Saccoccia, F., Brindisi, M., Gimmelli, R., Relitti, N., Guidi, A., Saraswati, A. P., Cavella, C., Brogi, S., Chemi, G., Butini, S., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00224 · Cited by 32
Self-citationStructure‐Based Design, Synthesis, and Biological Evaluation of Triazole‐Based smHDAC8 Inhibitors
Kalinin, D. V., Jana, S. K., Pfafenrot, M., Chakrabarti, A., Melesina, J., Shaik, T. B., Lancelot, J., Pierce, R. J., Sippl, W., Romier, C., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900583 · Cited by 30
Self-citationKim, J. Y., Han, S. Y., Yoo, J. H., Kim, G. W., Jeon, Y. H., Lee, S. W., Park, J., & Kwon, S. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158645 · Cited by 29
“Nevertheless, HDAC8 is an attractive therapeutic target and several HDAC8 selective inhibitors (HDAC8is) have been developed [30].”
BackgroundHDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates
Mak, J. Y. W., Wu, K., Gupta, P. K., Barbero, S., McLaughlin, M. G., Lucke, A. J., Tng, J., Lim, J., Loh, Z., Sweet, M. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01967 · Cited by 33
Xiao, Y., Awasthee, N., Liu, Y., Meng, C., He, M. Y., Hale, S. M., Karki, R., Lin, Z., Mosterio, M., Garcia, B. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00761 · Cited by 24
The clinical significance of histone deacetylase-8 in human breast cancer
Rahmani, G., Sameri, S., Abbasi, N., Abdi, M., & Najafi, R. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153396 · Cited by 22
Tang, H., Liang, Y., Shen, H., Cai, S., Yu, M., Fan, H., Ding, K., & Wang, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106112 · Cited by 27
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Steimbach, R. R., Herbst‐Gervasoni, C. J., Merz, A., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200180 · Cited by 22
Self-citationKarati, D., Mukherjee, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02303-x · Cited by 27
HDAC8 as a target in drug discovery: Function, structure and design
Zhao, Q., Liu, H., Peng, J., Niu, H., Liu, J., Xue, H., Liu, W., Liu, X., Hao, H., Zhang, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116972 · Cited by 25
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
Ghazy, E., Abdelsalam, M. A. M., Robaa, D., Pierce, R. J., & Sippl, W. (2022) · Pharmaceuticals · doi:10.3390/ph15010080 · Cited by 22
“The crystal structure of compound 6 in complex with smHDAC8 showed a similar binding mode as that classically adopted by meta-substituted benzhydroxamic acid derivatives (Figure 2A) [53].”
BackgroundMethodSelf-citationBaselious, F., Robaa, D., & Sippl, W. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107700 · Cited by 20
Self-citationKashyap, K., & Kakkar, R. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1567388 · Cited by 20
“For further validation of the IFD methodology, the above IFD pose of PCI-34051 was superimposed on the recently reported crystal structure of Schistosoma mansoni HDAC8 (smHDAC8) co-crystallized with PCI-34051 (PDB ID: 6HQY) (Marek et al., 2018).”
MethodMultiscale Workflow for Modeling Ligand Complexes of Zinc Metalloproteins
Yang, Z., Twidale, R. M., Gervasoni, S. I., Suardíaz, R., Colenso, C. K., Lang, E. J. M., SPENCER, J. M., & Mulholland, A. J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01109 · Cited by 21
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Vaca, H. R., Celentano, A. M., Toscanini, M. A., Heimburg, T., Ghazy, E., Zeyen, P., Hauser, A., Oliveira, G., Elissondo, M. C., Jung, M., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009226 · Cited by 21
“Similarly, the effects of the structure-based designed SmHDAC8 inhibitors TH65, EG18, and TB87 [30, 32, 42] on M. vogae viability were determined.”
BackgroundInfluentialSelf-citationSimoben, C. V., Ghazy, E., Zeyen, P., Darwish, S., Schmidt, M., Romier, C., Robaa, D., & Sippl, W. (2021) · Molecules · doi:10.3390/molecules26092584 · Cited by 17
“We used the same preparation protocol as in our earlier publications [50,52,54,71].”
MethodSelf-citationMarek, M., Ramos‐Morales, E., Picchi, G. F. A., Bayer, T., Norström, C., Herp, D., Sales-Junior, P. A., Guerra-Slompo, E. P., Hausmann, K., Chakrabarti, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110129 · Cited by 20
Self-citationAntitumor activity of novel POLA1-HDAC11 dual inhibitors
Dallavalle, S., Musso, L., Cincinelli, R., Darwiche, N., Gervasoni, S. I., Vistoli, G., Guglielmi, M. B., Porta, I. L., Pizzulo, M., Modica, E., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113971 · Cited by 18
Baselious, F., Hilscher, S., Hagemann, S., Tripathee, S., Robaa, D., Barinka, C., Hüttelmaier, S., Schutkowski, M., & Sippl, W. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400486 · Cited by 16
Self-citationYang, H. Y., Hur, G., Lee, T. K., Kim, J., Kim, J. H., Kim, J. R., Kim, J., Park, J. H. Y., & Lee, K. W. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300149 · Cited by 19
Hu, J., Fu, S., Zhan, Z., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116109 · Cited by 20
Ghazy, E., Heimburg, T., Lancelot, J., Zeyen, P., Schmidtkunz, K., Truhn, A., Darwish, S., Simoben, C. V., Shaik, T. B., Erdmann, F., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113745 · Cited by 15
Self-citationPromoter conservation in HDACs points to functional implications
Boltz, T. A., Khuri, S., & Wuchty, S. (2019) · BMC Genomics · doi:10.1186/s12864-019-5973-x · Cited by 14
Zhang, M., Ying, J. B., Wang, S., He, D., Zhu, H., Zhang, C., Tang, L., Lin, R., & Zhang, Y. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29583 · Cited by 15
“There are various modification strategies for the selective HDAC8 inhibitors, and increasing studies have pointed out that the selective inhibitory activity of the small molecules against HDAC8 is sensitive to the Cap modification.(24,25,33,34) Thus, it is necessary to explore how the Cap modifications affect the bind…”
Backgroundde Souza, L. Â., Bastos, M. S. E., Agripino, J. D. M., Onofre, T. S., Calla, L. F. A., Heimburg, T., Ghazy, E., Bayer, T., da Silva, V. H. F., Ribeiro, P. D., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114191 · Cited by 17
Self-citationA patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)
Banerjee, S., Ghosh, B., Jha, T., & Adhikari, N. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2391289 · Cited by 15
“Studies regarding the design and structural aspects disclosed three essential pharmacophoric features [5,10,17] (Figure 3(a)) that are essential for HDAC inhibition such as: (i) A Zn 2+ -binding group (ZBG) aids the chelation of the molecule with the catalytic Zn 2+ ion of HDAC isoforms present at…”
Zhao, L., Liang, Q., He, Y., Liu, M., Tong, R., Jiang, Z., Wang, W., & Shi, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106181 · Cited by 18
Development of New Inhibitors of HDAC1–3 Enzymes Aided by In Silico Design Strategies
Cheshmazar, N., Hemmati, S., Hamzeh‐Mivehroud, M., Sokouti, B., Zessin, M., Schutkowski, M., Sippl, W., Charoudeh, H. N., & Dastmalchi, S. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01557 · Cited by 13
Self-citationBanerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1704881 · Cited by 13
HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry
Rajaraman, S., Balakrishnan, R., Deshmukh, D., Ganorkar, A., Biswas, S., Pulya, S., & Ghosh, B. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0054 · Cited by 16
Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment
Mody, D., Bouckaert, J. M. J., Savvides, S. N., & Gupta, V. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917143953 · Cited by 13
“(2018) suggested a unique L-shaped conformation of the HDAC8-selective inhibitors which allows for them to bind to HDAC8 pocket formed by L1, L4, and catalytic Tyr, which is otherwise sterically locked to accommodate L-shaped inhibitors in HDAC1-3 isoforms (158).”
BackgroundBülbül, E. F., Robaa, D., Sun, P., Mahmoudi, F., Melesina, J., Zessin, M., Schutkowski, M., & Sippl, W. (2023) · Pharmaceuticals · doi:10.3390/ph16070968 · Cited by 13
Self-citationChemically Diverse S. mansoni HDAC8 Inhibitors Reduce Viability in Worm Larval and Adult Stages
Noce, B., Bello, E. D., Zwergel, C., Fioravanti, R., Valente, S., Rotili, D., Masotti, A., Ansari, M. S. Z., Trisciuoglio, D., Chakrabarti, A., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202200510 · Cited by 14
Self-citationHistone Deacetylase 2 (HDAC2) Inhibitors Containing Boron
Kavianpour, P., Gemmell, M., Kahlert, J. U., & Rendina, L. M. (2020) · ChemBioChem · doi:10.1002/cbic.202000131 · Cited by 11
González, F. P. G., & Mancilla, T. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104080 · Cited by 13
Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051
Luo, Y., Yan, Z., Chu, X., Zhang, Y., Qiu, Y., & Li, H. (2025) · Communications Biology · doi:10.1038/s42003-025-07649-0 · Cited by 11
“Thedynamicchangesintheseregionsiscon-sistentwiththehighplasticityofthehHDAC8bindingchannelasreported intheliterature 13,23,24 .”
InfluentialMorse, J. S., Sheng, Y. J., Hampton, J. T., Sylvain, L. D., Das, S. K., Alugubelli, Y. R., Chen, P. C., Yang, K. S., Xu, S., Fierke, C. A., et al. (2022) · Protein Science · doi:10.1002/pro.4512 · Cited by 9
“The pan-HDAC inhibitor quisinostat (HDAC IC50s: 0.11 to 119 nM; HDAC8 IC50: 4.26 nM) potently inhibits HDAC8, but failed to demonstrate superior results compared to vorinostat or romidepsin in phase 2 clinical trials for treating T-cell lymphoma.18-20 PCI-34051 is a highly selective HDAC8 inhibitor with a Ki = 10 nM.1…”
BackgroundInfluentialMoinul, M., Amin, S. A., Khatun, S., Das, S., Jha, T., & Gayen, S. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133967 · Cited by 10
Phosphorus containing analogues of SAHA as inhibitors of HDACs
Pun, M. D., Wu, H.-H., Olatunji, F. P., Kesic, B. N., Peters, J. W., & Berkman, C. E. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2063281 · Cited by 14
Saccoccia, F., Pozzetti, L., Gimmelli, R., Butini, S., Guidi, A., Papoff, G., Giannaccari, M., Brogi, S., Scognamiglio, V., Gemma, S., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102375 · Cited by 14
Huang, Y., Zhai, G., Fu, Y., Li, Y., Zang, Y., Lin, Y., & Zhang, K. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.003 · Cited by 9
Cheshmazar, N., Hamzeh‐Mivehroud, M., Hemmati, S., Abolhasani, H., Heidari, F., Charoudeh, H. N., Zessin, M., Schutkowski, M., Sippl, W., & Dastmalchi, S. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0122 · Cited by 7
Self-citationBuccheri, R., Coco, A., Pasquinucci, L., Amata, E., Marrazzo, A., & Rescifina, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020850 · Cited by 11
Huang, C., Shu, Y., Zhu, Y., Liu, H., Wang, X., Wen, H., Liu, J., & Li, W. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116821 · Cited by 7
Metalloenzyme Inhibitors against Zoonotic Infections: Focus on Leishmania and Schistosoma
Rossi, S., Tudino, V., Carullo, G., Butini, S., Campiani, G., & Gemma, S. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00163 · Cited by 8
Amin, S. A., Banerjee, S., Adhikari, N., & Jha, T. (2020) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2020.1723136 · Cited by 9
“The X-ray crystallographic study of HDAC8 and its potent HDAC8 inhibitor A010 (PDB: 6HQY) [13] showed the utility of the alkyl/aryl amide (substructure G15) in the biological activity (Figure 6).”
BackgroundJänsch, N., Lang, K. L., & Meyer‐Almes, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911775 · Cited by 9
“poses in wildtype smHDAC8 and “humanized” mutant variant smHDAC8H292M [20].”
BackgroundInfluentialAbdelsalam, M. A. M., Zmyslia, M., Schmidtkunz, K., Vecchio, A., Hilscher, S., Ibrahim, H. S., Schutkowski, M., Jung, M., Jessen‐Trefzer, C., & Sippl, W. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300536 · Cited by 5
Self-citationDiscovery of organosulfur-based selective HDAC8 inhibitors with anti-neuroblastoma activity
Cho, H., Lee, E., Kim, J., Shin, S., Kim, Y. J., Lee, H., Yu, J. H., Jeon, Y. H., Lee, S. W., Lee, S. Y., et al. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106921 · Cited by 7
Medicinal chemistry of histone deacetylase inhibitors
Ružić, D., Djoković, N., Nikolic, K. M., & Vujić, Z. B. (2021) · Arhiv za farmaciju · doi:10.5937/arhfarm71-30618 · Cited by 6
Lowe, B. D., & Fletcher, S. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130312 · Cited by 6
An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices
Yan, Y., Huang, C., Shu, Y., Wen, H., Shan, C., Wang, X., Liu, J., & Li, W. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob01367j · Cited by 5
Khatun, S., Islam, R., Amin, S. A., Bhattacharya, A., Dhaked, D. K., Jha, T., & Gayen, S. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2442756 · Cited by 5
“Previous study (Marek et al., 2018) has suggested that N - heterocycles, like the triazole ring, play a role in adopting a distinctive L-shaped conformation, facilitating the binding of inhibitors to a specific pocket within the HDAC8 enzyme.”
Replacement of the hydroxamic acid group in the selective HDAC8 inhibitor PCI-34051
Long, K. E., Close, D. A., Johnston, P. A., & Huryn, D. M. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129810 · Cited by 4
Peng, Y., Gao, Q., Wang, Y., Yao, Q., & Zhang, J. (2021) · ChemMedChem · doi:10.1002/cmdc.202001004 · Cited by 4
Recent research progress on small molecule compounds and its derivatives of antiparasitic drugs
Wang, T., Wang, L., He, J., Li, C., & Shi, J. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108359 · Cited by 3
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Sehr, P. A., Gunkel, N., Miller, A. K., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12440096.v3 · Cited by 2
Self-citationBandaru, N. V. M. R., Fathima, A., Joshi, V., Schweipert, M., Pathur, O., Chaitanya, K. S., Trinath, J., Sharma, V., Abbineni, C., Meyer‐Almes, F., et al. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100255 · Cited by 4
Gupta, J., & Izard, T. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110394 · Cited by 3
Zhai, S., Kemkes, M., Kponomaizoun, C.-E., Gerhartz, J., Feller, F., Tu, J., Pieńkowska, D. E., Schliehe‐Diecks, J., Dressel, I., Gütschow, M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00939 · Cited by 3
Phenotypic Screening of Histone Deacetylase (HDAC) Inhibitors against Schistosoma mansoni
Hassan, M. M., Sedighi, A., Olaoye, O. O., Häberli, C., Merz, A., Ramos‐Morales, E., de Araujo, E. D., Romier, C., Jung, M., Keiser, J., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202100622 · Cited by 4
Self-citationThe Role of Amide-π Stacking in Resolving the DMF-Benzene Miscibility Paradox
Zhao, Z., Chen, T., Zhou, K., Su, P., Xie, Z., Huang, Y., Meng, L., Nan, Z., & Lu, C. (2025) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.5c02817 · Cited by 3
Gimmelli, R., Papoff, G., Saccoccia, F., Lalli, C., Gemma, S., Campiani, G., & Ruberti, G. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0011992 · Cited by 4
Daniel, L., Gotsbacher, M. P., Richardson‐Sanchez, T., Tieu, W., & Codd, R. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.08.002 · Cited by 4
Lin, X., Zhou, J., Chen, S., Long, Y., & Yu, Z.-G. (2026) · Expert Systems with Applications · doi:10.1016/j.eswa.2026.131109 · Cited by 3
Dews, E. A., Teixeira, J. E., Huston, C. D., Meyers, M. J., & Hyson, P. R. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-25 · Cited by 3
Porter, N. J., & Christianson, D. W. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.06.029 · Cited by 2
“To date, many human HDAC8-inhibitor complexes have been structurally characterized (Somoza et al., 2004; Vannini et al., 2004, 2007; Dowling et al., 2008, 2010; Cole et al., 2011; Whitehead et al., 2011; Decroos et al., 2014, 2015a,b; Gantt et al., 2016; Tabackman et al., 2016; Porter et al., 2016, 2017; Marek et al.,…”
BackgroundRamírez, J. E. G., & Mancilla, T. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14323 · Cited by 1
“Besides, molecular docking study has also been a useful tool to design and investigate new HDAC8 inhibitors (HDAC8i) (Banerjee et al., 2019; Marek et al., 2018; Uba et al., 2019; Yang et al., 2019).”
MethodBanerjee, S., Baidya, S. K., Jha, T., Ghosh, B., & Adhikari, N. (2024) · Medicinal Chemistry · doi:10.2174/0115734064329669241007060848 · Cited by 1
Chotitumnavee, J., Seemaung, P., Settacomkul, R., Sukprasert, R., Itoh, Y., Suzuki, T., Srihirun, S., Power, C., & Vivithanaporn, P. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s555228 · Cited by 2
Self-citationLong, N., Meyer‐Almes, F., Kopranovic, A., & Wren, S. P. (2026) · ChemMedChem · doi:10.1002/cmdc.70270 · Cited by 2
“Notably, this structure corresponds to HDAC8 from Schistosoma mansoni (smHDAC8), which has been widely used as a structural surrogate due to its high degree of homology with the human enzyme [23].”
Metadata
- Authors
- Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., Schmidtkunz, K., Suzuki, T., Holl, R., Ennifar, E., Pierce, R. J., Jung, M., Sippl, W., & Romier, C.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Martin Luther University Halle-Wittenberg (DE)
- University of Freiburg (DE)
- Institut de Génétique et Biologie Moléculaire et Cellulaire (IGBMC), Département de Biologie Structurale Intégrative, Université de Strasbourg, Centre National de la Recherche Scientifique (CNRS UMR7104), Institut National de la Santé et de la Recherche Médicale (INSERM U1258), 1 rue Laurent Fries, 67404 Illkirch Cedex, France
- University of Münster (DE)
- Kyoto Prefectural University of Medicine (JP)
- Universität Hamburg (DE)
- Corresponding author
- Marek, Martin
- Romier, Christophe
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-10-22
- Volume
- 61
- Issue
- 22
- Pages
- 10000-10016
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2897192913
- Cited by
- 122
- References
- 80
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 16 · 2023: 14 · 2022: 19 · 2021: 16 · 2020: 18 · 2019: 10 · 2018: 1
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- green
- cnrs.hal.science
- Licence
- other-oa
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02)
- Deutsche Forschungsgemeinschaft (Si868/13-1, Ju295/13-1)
- Seventh Framework Programme (241865, 602080)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- HDAC8, catalytic tyrosine, protein engineering, epigenetic drug design, chemical probes, epigenetic regulators
- MeSH terms
- Amino Acid Sequence, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Repressor Proteins, Structure-Activity Relationship, Substrate Specificity, Triazoles, Catalytic Domain, Molecular Dynamics Simulation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.